Interestingly, KRAS mutations have been shown to induce an immunosuppressive phenotype in CRC through different means, including downregulation of MHC class I molecules and conversion of CD4+ cells to Tregs [90], and recent preclinical studies demonstrated an immunomodulatory role for KRAS inhibitors. This evidence concerns the gene KRAS and colorectal carcinoma.